Crispr Therapeutics (NASDAQ:CRSP) had its target price increased by Roth Capital from $65.00 to $100.00 in a research note issued to investors on Tuesday, November 19th, The Fly reports.
A number of other equities analysts also recently commented on CRSP. BidaskClub upgraded shares of Crispr Therapeutics from a hold rating to a buy rating in a research note on Friday, November 15th. Wells Fargo & Co reiterated a buy rating on shares of Crispr Therapeutics in a research note on Tuesday, November 19th. Barclays boosted their target price on shares of Crispr Therapeutics from $59.00 to $62.00 and gave the stock an overweight rating in a research note on Tuesday, July 30th. Zacks Investment Research cut shares of Crispr Therapeutics from a hold rating to a sell rating in a research report on Monday, September 30th. Finally, TheStreet raised shares of Crispr Therapeutics from a d rating to a c rating in a research report on Monday, October 28th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and fourteen have assigned a buy rating to the company. The stock currently has an average rating of Buy and a consensus target price of $69.54.
Shares of CRSP stock traded down $0.67 on Tuesday, reaching $65.36. 737,055 shares of the stock were exchanged, compared to its average volume of 1,674,626. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. The business’s 50 day moving average price is $58.93 and its 200 day moving average price is $48.44. The company has a market capitalization of $3.65 billion, a price-to-earnings ratio of -19.00 and a beta of 3.31. Crispr Therapeutics has a twelve month low of $22.22 and a twelve month high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, topping analysts’ consensus estimates of ($0.95) by $3.35. The firm had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. Equities research analysts forecast that Crispr Therapeutics will post 0.65 earnings per share for the current year.
In other news, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total value of $412,500.00. Following the completion of the sale, the director now directly owns 7,500 shares of the company’s stock, valued at $412,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now directly owns 33,618 shares of the company’s stock, valued at $2,353,260. The disclosure for this sale can be found here. Over the last three months, insiders sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is owned by corporate insiders.
Large investors have recently made changes to their positions in the company. NEXT Financial Group Inc raised its holdings in shares of Crispr Therapeutics by 915.0% in the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock valued at $25,000 after buying an additional 549 shares during the last quarter. Benjamin Edwards Inc. raised its holdings in shares of Crispr Therapeutics by 96.4% in the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock valued at $26,000 after buying an additional 268 shares during the last quarter. Coastal Investment Advisors Inc. purchased a new stake in shares of Crispr Therapeutics in the third quarter valued at about $26,000. US Bancorp DE raised its holdings in shares of Crispr Therapeutics by 553.7% in the second quarter. US Bancorp DE now owns 621 shares of the company’s stock valued at $29,000 after buying an additional 526 shares during the last quarter. Finally, BSW Wealth Partners purchased a new stake in shares of Crispr Therapeutics in the second quarter valued at about $39,000. 49.82% of the stock is owned by institutional investors and hedge funds.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Article: What Are Treasury Bonds?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.